| Index | — | P/E | — | EPS (ttm) | -1.06 | Insider Own | 0.17% | Shs Outstand | 266.16M | Perf Week | -7.19% |
| Market Cap | 377.95M | Forward P/E | — | EPS next Y | -0.63 | Insider Trans | -1.50% | Shs Float | 240.53M | Perf Month | -20.22% |
| Enterprise Value | 253.95M | PEG | — | EPS next Q | -0.21 | Short Float | 3.77% | Perf Quarter | -27.18% | ||
| Income | -280.00M | P/S | 3.23 | EPS this Y | — | Short Ratio | 4.27 | Perf Half Y | -9.55% | ||
| Sales | 117.00M | P/B | 5.04 | EPS next Y | — | ROA | -56.77% | Short Interest | 9.07M | Perf YTD | -28.64% |
| Book/sh | 0.28 | P/C | 1.87 | EPS next 5Y | — | ROE | -178.58% | 52W High | 2.58 -44.96% | Perf Year | -5.96% |
| Cash/sh | 0.76 | P/FCF | — | EPS past 3/5Y | — | ROIC | -57.49% | 52W Low | 1.18 20.34% | Perf 3Y | -47.21% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 133.11% 106.99% | Gross Margin | 15.66% | Volatility | 6.94% 5.71% | Perf 5Y | -74.69% |
| Dividend TTM | — | EV/Sales | 2.17 | EPS Y/Y TTM | — | Oper. Margin | -210.76% | ATR (14) | 0.10 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 4.40 | Sales Y/Y TTM | 290.00% | Profit Margin | -238.62% | RSI (14) | 31.87 | Recom | 2.21 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.89 | EPS Q/Q | 16.67% | SMA20 | -13.34% | Beta | 2.35 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 1.04 | Sales Q/Q | 119.05% | SMA50 | -24.76% | Rel Volume | 2.23 | Prev Close | 1.52 |
| Employees | 752 | LT Debt/Eq | 1.04 | Earnings | Nov 10 | SMA200 | -14.77% | Avg Volume | 2.11M | Price | 1.42 |
| IPO Date | Jun 22, 2018 | Option/Short | No / Yes | EPS/Sales Surpr. | 22.80% 18.49% | Net Debt/EBITDA | — | Volume | 4,704,229 | Change | -6.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman Sachs | Neutral → Buy | |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy | |
| May-20-24 | Reiterated | Wells Fargo | Overweight | |
| Mar-10-21 | Downgrade | Redburn | Buy → Neutral | |
| Mar-09-21 | Downgrade | Redburn | Buy → Neutral | |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2017 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 117 | 76 | 10 | 2 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 99 | 97 | 141 | 0 | — | — | — | — | — | |
| Gross Profit | 19 | -21 | -131 | 2 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 153 | 132 | 0 | 47 | — | — | — | — | — | |
| Research and Development | 113 | 129 | 158 | 130 | — | — | — | — | — | |
| Other Operating Expense | -1 | -1 | -47 | 4 | — | — | — | — | — | |
| Operating Income | -248 | -281 | -241 | -180 | — | — | — | — | — | |
| Interest Expense | 48 | 37 | 9 | 45 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 21 | 32 | 16 | — | — | — | — | — | |
| Net Income Before Taxes | -280 | -297 | -219 | -208 | — | — | — | — | — | |
| Income Taxes | 1 | -9 | 2 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -280 | -288 | -221 | -208 | — | — | — | — | — | |
| Net Income From Continuing Operations | -280 | -288 | -221 | -208 | — | — | — | — | — | |
| Net Income | -280 | -288 | -221 | -208 | — | — | — | — | — | |
| EPS (Recurring) | -1.06 | -1.08 | -0.87 | -1.20 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.06 | -1.08 | -0.87 | -1.20 | — | — | — | — | — | |
| EPS (Diluted) | -1.06 | -1.08 | -0.87 | -1.20 | — | — | — | — | — | |
| EBITDA | -221 | -250 | -233 | -157 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.23 | 6.97 | 59.93 | 560.28 | — | — | — | — | — | |
| Gross Margin | 16.24 | -27.63 | -1,310.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -211.97 | -369.74 | -2,410.00 | -9,000.00 | — | — | — | — | — | |
| Net Margin | -239.32 | -378.95 | -2,210.00 | -10,400.00 | — | — | — | — | — | |
| Shares Outstanding | 266 | 266 | 255 | 174 | — | — | — | — | — | |
| Market Capitalization | 378 | 529 | 599 | 1,121 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Piccina Cintia | U.S. CCO & Country Gen Manager | Sep 02 '26 | Sale | 2.34 | 6,713 | 15,682 | 13,287 | Sep 03 |
| Piccina Cintia | U.S. CCO & Country Gen Manager | Sep 01 '26 | Option Exercise | 2.35 | 20,000 | 47,000 | 20,000 | Sep 03 |